Trial Profile

A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KITE)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Nov 2022 Results assessing the safety and efficacy of brolucizumab 6mg vs aflibercept 2mg in diabetic macular edema presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
20 Jun 2022 Results published in the Novartis Media Release
20 Jun 2022 According to a Novartis media release, based on year one data from the Phase III KESTREL and KITE studies, the European Commission (EC) has approved Beovu (brolucizumab) 120 mg / mL for the treatment of visual impairment due to diabetic macular edema (DME).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com